Saima Baig
Adult Health · Bridgeton, MONPI 1033619044
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 679 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations. Among adult health clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 679 payments — averaging $17.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Neurocrine Biosciences, Inc.$1K
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Alkermes, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$1K
- plus $4K from 28 others
What the payments were for
- Food & beverage$11,92898%
- Education$2802%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 149 | $2,141 |
| Neurocrine Biosciences, Inc. | 73 | $1,459 |
| AbbVie | 63 | $1,266 |
| Otsuka America Pharmaceutical, Inc. | 75 | $1,155 |
| Alkermes, Inc. | 51 | $1,106 |
| Teva Pharmaceuticals USA, Inc. | 50 | $1,043 |
| Sunovion Pharmaceuticals Inc. | 34 | $525 |
| Lundbeck LLC | 25 | $455 |
| Vanda Pharmaceuticals Inc. | 19 | $399 |
| Acadia Pharmaceuticals Inc | 19 | $398 |
| Axsome Therapeutics, Inc. | 20 | $317 |
| Johnson & Johnson | 14 | $304 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $281 |
| Supernus Pharmaceuticals, Inc. | 10 | $232 |
| E.r. Squibb & Sons, L.L.C. | 9 | $204 |
| Bausch Health US, LLC | 10 | $188 |
| Tris Pharma Inc | 5 | $88 |
| Jazz Pharmaceuticals Inc. | 5 | $81 |
| Merck | 5 | $74 |
| Noven Therapeutics, LLC | 4 | $70 |
| Adlon Therapeutics L.p. | 4 | $61 |
| Indivior Inc. | 3 | $46 |
| Neos Therapeutics, LP | 2 | $44 |
| Avanir Pharmaceuticals, Inc. | 2 | $42 |
| Almatica Pharma LLC | 3 | $41 |
| Validus Pharmaceuticals LLC | 2 | $32 |
| Orexo US, Inc. | 1 | $28 |
| Noven Pharmaceuticals, Inc. | 1 | $22 |
| Collegium Pharmaceutical, Inc. | 1 | $21 |
| Ironshore Pharmaceuticals Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $19 |
| Luye Pharma (USA) Ltd. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Eisai Inc. | 1 | $12 |
How this compares
$12,208 in reported general payments places this provider in the 95th percentile of 555 adult health providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 44 | $369,279 |
| AustedoDeutetrabenazine | 12 | $173,425 |
| RexultiBrexpiprazole | 76 | $115,267 |
| VraylarCariprazine Hcl | 65 | $98,481 |
| CaplytaLumateperone Tosylate | 50 | $88,347 |
| Invega SustennaPaliperidone Palmitate | 38 | $86,451 |
| Invega TrinzaPaliperidone Palmitate | 12 | $82,583 |
| Abilify MaintenaAripiprazole | 11 | $31,182 |
| TrintellixVortioxetine Hydrobromide | 59 | $29,577 |
| Aripiprazole | 239 | $23,232 |
| Lurasidone Hcl | 104 | $20,701 |
| Risperidone ErRisperidone Microspheres | 23 | $11,297 |
| Duloxetine Hcl | 333 | $8,588 |
| Quetiapine Fumarate | 420 | $4,928 |
| Paliperidone ErPaliperidone | 30 | $4,810 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,459 | $369,27944 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $1,043 | $173,42512 claims |
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $304 | $169,03450 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,155 | $146,44987 claims |
| AbbVieVraylar | $1,266 | $98,48165 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $2,141 | $88,34750 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $281 | $29,57759 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 555 adult health providers in Missouri.
Other adult health in Bridgeton
- Allyson GrandenBridgeton$10K
- Tabitha StithChesterfield$300K
- Stephanie VogelSaint Louis$115K
- Racquel FrisellaChesterfield$110K
- Shannon TuckerSaint Louis$93K
- Laurencia KlipfelSaint Louis$79K
- Maria WallsSaint Louis$69K
- Patrick BehnkeChesterfield$54K
- Elaine ZobristFenton$38K
- Yolanda Thompson MartinKansas City$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.